KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation and Depletion (2021 - 2025)

Historic Depreciation and Depletion for Emergent BioSolutions (EBS) over the last 5 years, with Q3 2025 value amounting to $7.1 million.

  • Emergent BioSolutions' Depreciation and Depletion fell 2970.3% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year decrease of 2995.78%. This contributed to the annual value of $43.7 million for FY2024, which is 2655.46% down from last year.
  • Emergent BioSolutions' Depreciation and Depletion amounted to $7.1 million in Q3 2025, which was down 2970.3% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Depreciation and Depletion peaked at $28.5 million during Q2 2022, and registered a low of $7.1 million during Q3 2025.
  • Over the past 5 years, Emergent BioSolutions' median Depreciation and Depletion value was $13.6 million (recorded in 2021), while the average stood at $14.3 million.
  • In the last 5 years, Emergent BioSolutions' Depreciation and Depletion surged by 5405.41% in 2022 and then tumbled by 4236.45% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Depreciation and Depletion (Quarter) stood at $15.7 million in 2021, then grew by 14.65% to $18.0 million in 2022, then dropped by 25.56% to $13.4 million in 2023, then fell by 27.61% to $9.7 million in 2024, then decreased by 26.8% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q3 2025, $7.3 million for Q2 2025, and $9.1 million during Q1 2025.